The global women’s health market size is projected to reach USD 41.05 billion by 2027, exhibiting a CAGR of 3.2% during the forecast period. The COVID-19 pandemic is likely to reemphasize the importance of women’s health and boost the market, observes Fortune Business Insights™ in its report, titled “Women’s Health Market Size, Share & Industry Analysis, By Application (Contraceptives, Osteoporosis, Menopause, Infertility, and Others) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2020-2027”.

For more information visit :

As per the report, the global market value stood at USD 35.02 billion. The salient features of the report include:

  • In-depth evaluation of the market trends, drivers, and restraints;
  • Careful examination of the different market segments;
  • Microscopic assessment of the regional and competitive developments influencing the market growth; and
  • Broad-based understanding of the overall industry outlook and opportunities.


An Overview of the Impact of COVID-19 on this Market :

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.


Request a Sample Copy of the Research Report:

List of Key Companies Profiled in the Women’s Health Market Report:

  • Agile Therapeutics (New Jersey, USA)
  • LUPIN (Mumbai, India)
  • Merck & Co., Inc. (New Jersey, United States)
  • Amgen Inc. (California, United States)
  • Bayer AG (Leverkusen, Germany)
  • AstraZeneca (Cambridge, UK)
  • Eli Lilly and Company (Indiana, United States)
  • Novartis AG (Basel, Switzerland)
  • Pfizer Inc. (New York, United States)